#Pfizer #Eliquis #BMS #pharmanews #Padcev #Astellas #Lorbrena #costsavings #costcuttinginitiatives #restructuring #BioNTech #COVID19vaccine #costofgoodssold #COGS #generics #bladdercancer #lungcancer #RandD #oncology #obesity #Metsera #patients #patentloss
zurl.co/LrplA
zurl.co/LrplA
Pfizer targets $2.5bn more in cost savings
Pfizer's second-quarter results update is headlined by news of an additional $2.5 billion in cost-cutting initiatives.
pharmaphorum.com
August 10, 2026 at 1:12 PM